Alkermes (ALKS) Accounts Payables (2011 - 2026)
Alkermes' (ALKS) quarterly Accounts Payables came in at $292.6 million in Q1 2026, up 57.27% year-on-year from $186.0 million in Q1 2025, and up 1.04% on a QoQ basis from $289.6 million in Q4 2025.
Alkermes (ALKS) Accounts Payables (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Accounts Payables data on file, last reported at $292.6 million in Q1 2026.
- On a quarterly basis, Accounts Payables rose 57.27% year-over-year to $292.6 million in Q1 2026; TTM through Mar 2026 was $292.6 million, a 57.27% increase from a year earlier, with the FY2025 full-year figure at $289.6 million, up 56.24% from the prior year.
- Accounts Payables for Q1 2026 stood at $292.6 million, up from $289.6 million in the prior quarter.
- Over the last five years, Accounts Payables for ALKS reached as high as $292.6 million in Q1 2026 and fell as low as $27.7 million in Q1 2022.
- Historically, Accounts Payables has averaged $167.7 million across 5 years, with a median of $186.0 million in 2025.
- Across the five-year window, Accounts Payables plunged 91.83% in 2022 and surged 506.59% in 2023, its largest moves.
- Year by year, Accounts Payables stood at $220.1 million in 2022, then climbed by 9.3% to $240.6 million in 2023, then decreased by 22.96% to $185.3 million in 2024, then surged by 56.24% to $289.6 million in 2025, then increased by 1.04% to $292.6 million in 2026.
- Per Business Quant data, the three most recent Accounts Payables figures were $292.6 million in Q1 2026, $289.6 million in Q4 2025, and $215.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 4.96 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 2.60 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 507.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.13 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 498.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 1.67 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.75 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 773.00 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 372.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | 292.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 292.58 Mn |
| Dec 31, 2025 | 289.57 Mn |
| Sep 30, 2025 | 214.99 Mn |
| Jun 30, 2025 | 99.21 Mn |
| Mar 31, 2025 | 186.04 Mn |
| Dec 31, 2024 | 185.33 Mn |
| Sep 30, 2024 | 160.20 Mn |
| Jun 30, 2024 | 239.77 Mn |
| Mar 31, 2024 | 77.05 Mn |
| Dec 31, 2023 | 240.56 Mn |
| Sep 30, 2023 | 87.04 Mn |
| Jun 30, 2023 | 242.92 Mn |
| Mar 31, 2023 | 37.15 Mn |
| Dec 31, 2022 | 220.09 Mn |
| Sep 30, 2022 | 211.18 Mn |
| Jun 30, 2022 | 40.05 Mn |
| Mar 31, 2022 | 27.70 Mn |
| Dec 31, 2021 | 55.72 Mn |
| Sep 30, 2021 | 428.03 Mn |
| Jun 30, 2021 | 357.96 Mn |